The effect of mud pack therapy on serum YKL-40 and hsCRP levels in patients with knee osteoarthritis

Garnero P, Delmas PD (2003) Biomarkers in osteoarthritis. Curr Opin Rheumatol 15:641–646

Abe M, Takahashi M, Naitou K, Ohmura K, Nagano A (2003) Investigation of generalized osteoarthritis by combining X-ray grading of the knee, spine and hand using biochemical markers for arthritis in patients with knee osteoarthritis. Clin Rheumatol 22:425–431

Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, Delmas PD (2002) Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 46:2613–2624

Vignon E, Garnero P, Delmas P et al (2001) Recommendations for the registration of drugs used in the treatment of osteoarthritis: an update on biochemical markers. Osteoarthr Cartil 4:289–293

Harvey S, Weisman M, O’Dell J, Scott T, Krusemeier M, Visor J, Swindlehurst C (1998) Chondrex: new marker of joint disease. Clin Chem 44:509–516

Hakala BE, White C, Recklies AD (1993) Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 268:25803–25810

Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I, Price PA (1996) Serum YKL-40 levels on healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 35:553–559

Volck B, Ostergaard K, Jhansen JS, Garbarsch C, Price PA (1999) The distribution of YKL-40 in osteoarthritic and normal human cartilage. Scand J Rheumatol 28:171–179

Volck B, Johansen JS, Stoltenberg M et al (2001) Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthr Cartil 9:203–214

Conrozier T, Carlier MC, Mathieu P, Colson F, Debard AL, Richard S, Favret H, Bienvenu J, Vignon E (2000) Serum levels of YKL-40 and C reactive protein in patients with hip osteoarthritis and healthy subjects: a cross sectional study. Ann Rheum Dis 59:828–831

Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E (2001) Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 60:619–626

Connor JR, Dodds RA, Emery JG, Kirkpatrick RB, Rosenberg M, Gowen M (2000) Human cartliage glycoprotein 39 (HC-gp 39) mRNA expression in adult and fetal chondrocytes, osteoblasts and osteocytes by in situ hybridization. Osteoarthr Cartil 8:87–95

Kawasaki M, Hasegawa Y, Kondo S, Iwata H (2001) Concentration and localization of YKL-40 in hip joint diseases. J Rheumatol 28:341–345

Wolfe F (1997) The C-reactive protein but not erythrocyte sedimentation rate is associated with clinical severity in patients with osteoarthritis of the knee or hip. J Rheumatol 8:1486–1488

Sowers M, Jannausch M, Stein E, Jamadar D, Hochberg M, Lachance L (2002) C-reactive protein as a biomarker of emergent osteoarthritis. Osteoarthr Cartil 10:595–601

Sturmer T, Brenner H, Koenig W, Gunther KP (2004) Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein. Ann Rheum Dis 63:200–205

Pearle AD, Scanzello CR, George S, Mandl LA, DiCarlo EF, Peterson M, Sculco TP, Crow MK (2007) Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthr Cartil 15:516–523

Lange U, Müller-Lander U, Schmidt KL (2006) Balneotheraphy in rheumatic diseases: an overview of novel and known aspect. Rheumatol Int 26:497–499

Zhang W, Doherty M, Arden N et al (2005) EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 64:669–681

Flusser D, Abu-Shakra M, Friger M, Codish S, Sukenik S (2002) Therapy with mud compresses for knee osteoarthritis: comparison of natural mud preparations with mineral-depleted mud. J Clin Rheumatol 8:197–203

Evcik D, Kavuncu V, Yeter A, Yigit I (2007) The efficacy of balneotherapy and mud-pack therapy in patients with knee osteoarthritis. Joint Bone Spine 74:60–65

Codish S, Abu-Shakra M, Flusser D, Friger M, Sukenik S (2005) Mud compress therapy for the hands of patients with rheumatoid arthritis. Rheumatol Int 25:49–54

Sukenik S, Buskila D, Neumann L, Kleiner-Baumgarten A, Zimlichman S, Horowitz J (1990) Sulphur bath and mud pack treatment for rheumatoid arthritis at the Dead Sea area. Ann Rheum Dis 49:99–102

Elkayam O, Ophir J, Brener S, Paran D, Wigler I, Efron D, Even-Paz Z, Politi Y, Yaron M (2000) Immediate and delayed effects of treatment at the Dead Sea in patients with psoriatic arthritis. Rheumatol Int 19:77–82

Fioravanti A, Perpignano G, Tirri G, Cardinale G, Gianniti C, Lanza CE, Loi A, Tirri E, Sfriso P, Cozzi F (2007) Effects of mud-bath treatment on fibromyalgia patients: a randomized clinical trial. Rheumatol Int 27:1157–1161

Sert F (2008) Osteoartrit hastalarında YKL-40 ve yüksek-duyarlıklı CRP (hsCRP) düzeylerinin değerlendirilmesi. Dissertation, University of Pamukkale

Bellamy N, Buchanan WW, Goldsmith CH, Campbell SLW (1988) Validation of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840

Tüzün EH, Eker L, Aytar A (2005) Acceptability, reliability, validity and responsiveness of the Turkish version of WOMAC osteoarthritis index. Osteoarthr Cartil 13:28–33

Martini CJM, Waugh IM (1978) A method for self-assessment of disability before and after hip replacement operation. BMJ 2:258–259

Kucukdeveci AA, McKenna SP, Kutlay S, Gursel Y, Whalley D, Arasil T (2000) The development and psychometric assessment of the Turkish version of the Nottingham health profile. Int J Rehabil Res 23(1):31–38

Odabaşı E, Turan M, Erdem H, Pay S, Güleç M, Karagülle MZ (2009) The effect of Mud pack treatment in knee osteoarthritis. Turk J Rheumatol 24:72–76

Fioravanti A, Iacoponi F, Bellisai B, Cantarini L, Galeazzi M (2010) Short- and long-term effects of spa therapy in knee osteoarthritis. Am J Phys Med Rehabil 89(2):125–132

Tolomio C, Ceschi-Berrini C, Moschin E, Galzigna L (1999) Colonization by diatoms and antirheumatic activity of thermal mud. Cell Biochem Funct 17:169–175

Sulenik S, Abu-Shakra M, Flusser D (1997) Balneotheraphy in autoimmun disease. Isr J Med Sci 33:258–261

Ghersetich I, Freedman D, Lotti T (2000) Balneology today. J Eur Acad Dermatol Venereol 14:346–348

Beer AM, Junginger HE, Lukanov J, Sagorchev P (2003) Evaluation of the permeation of peat substances through human skin in vitro. Int J Pharm 253:169–175

Beer AM, Lukanov J, Sagorchev P (2000) Mechanism of the effect of aqueous peat extract on spontaneous contractile activity of smooth muscles. Forsch Komplementärmed Klass Naturheilkd 7:237–241

Odabasi E, Turan M, Erdem H, Tekbas F (2008) Does mud pack treatment have any effect? A randomized controlled clinical study. J Altern Complement Med 14:559–565

Cechettin M, Bellometti S, Lalli A, Galzigna L (1995) Serum interleukin-1 changes in arthrosis patients after mud-pack treatment. Phys Rehab Kur Med 5:92–93

Bellometti S, Galzigna L (1998) Serum levels of a prostaglandin and a leukotriene after thermal mud pack therapy. J Investig Med 46:140–145

Bellometti S, Richelmi P, Tassoni T et al (2005) Production of matrix metalloproteinases and their inhibitors in osteoarthritic patients undergoing mud-bath therapy. Int J Clin Pharmacol Res 25:77–94

Bellometti S, Galzigna L, Richelmi P et al (2002) Both serum receptors of tumor necrosis factor are influenced by mud-pack treatment in osteoarthritic patients. Int J Tissue React 24:57–64

Bellometti S, Giannini S, Sartori L, Crepaldi G (1997) Cytokine levels in osteoarthrosis patients undergoing mud bath therapy. Int J Clin Pharmacol Res 17:149–153

Bellometti S, Cecchettin M, Galzigna L (1997) Mud pack therapy in osteoarthrosis: changes in serum levels of chondrocyte markers. Clin Chim Acta 268:101–106

Bellometti S, Poletto M, Gregotti C, Richelmi P, Berte F (2000) Mud bath therapy influences nitric oxide, myeloperoxidase and glutathione peroxidase serum levels in arthritic patients. Int J Clin Pharmacol Res 20(3–4):69–80

Swaak AJ, van Rooyen A, Nieuwenhuis E, Aarden LA (1988) Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. Scand J Rheumatol 17:469–474

Abramson SB, Attur M, Amin AR, Clancy R (2001) Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis. Curr Rheumatol Rep 3:535–541

Westacott CI, Whicher JT, Barnes IC, Thompson D, Swan AJ, Dieppe PA (1990) Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann Rheum Dis 49:676–681

Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M (1989) Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest 83:585–592

Ridker PM (2001) High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103:1813–1818